Momenta blocks Watson's US launch of generic Lovenox
This article was originally published in Scrip
A US District Court for the District of Massachusetts has granted a motion from Momenta Pharmaceuticals for a preliminary injunction preventing Watson Pharmaceuticals and Amphastar from selling enoxaparin sodium injection, a generic version of Sanofi's Lovenox. On 31 October, Momenta's shares shot up by 21%, or $2.56, to $14.80. The injunction, however, is subject to appeal.